Xintela publishes interim report for the third quarter of 2020

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2020-30 Sep 2020)· Net sales amounted to TSEK 0 (3).· Loss before tax totalled TSEK 24,922 (loss: 28,081).· Loss per share* was SEK 0.43 (loss: 0.71).· At 30 September 2020, […]

Xintela publishes interim report for the third quarter

Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]

Year-end Report 2018

The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]

Year-end Report 2017

Strategic decisions, collaboration agreements and financing Xintela took major steps forward in 2017 and there is every reason to be optimistic about the new year. Our unique stem cell technology and the decision to establish our own GMP facility for stem cell production have made us a player to reckon with in regenerative medicine. We […]